Phase III study of the efficacy and tolerability of lenvatinib monotherapy in patients with malignant melanoma

Trial Profile

Phase III study of the efficacy and tolerability of lenvatinib monotherapy in patients with malignant melanoma

Planning
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2009

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 25 Nov 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top